HIV protease inhibitor ritonavir increases endothelial monolayer permeability

Biochemical and Biophysical Research Communications

Volumn 335, Issue 3, 2005, Pages 874-882

  Chen, Changyi ^a   Lu, Xiang Huai ^b   Yan, Shaoyu ^a   Chai, Hong ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Barrier function; Endothelial cell; ERK1 2; HIV protease inhibitor; Oxidative stress; Permeability; Ritonavir; Superoxide; Tight junction molecule

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTIOXIDANT; CLAUDIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OCCLUDIN; PROTEINASE INHIBITOR; RITONAVIR; SB 303580; SELENOMETHIONINE; SUPEROXIDE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; TIMED DRUG RELEASE; VASCULAR LESION;

ANTIGENS, CD; BASE SEQUENCE; CADHERINS; CELL MEMBRANE PERMEABILITY; DNA PRIMERS; ENDOTHELIUM, VASCULAR; HIV PROTEASE INHIBITORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; RITONAVIR; RNA, MESSENGER; SUPEROXIDES; TIGHT JUNCTIONS;

EID: 23944445297     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.07.155     Document Type: Article

References (34)

1. A.G. Tomasselli, and R.L. Heinrikson Targeting the HIV-protease in AIDS therapy: a current clinical perspective Biochim. Biophys. Acta 1477 2000 189 214
2. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, http://www.aidsinfo.nih.gov.
3. B. Gallet, M. Pulik, P. Genet, P. Chedin, and M. Hiltgen Vascular complications associated with use of HIV protease inhibitors Lancet 351 1998 1958 1959
4. J.H. Stein, M.A. Klein, J.L. Bellehumeur, P.E. McBride, D.A. Wiebe, J.D. Otvos, and J.M. Sosman Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction Circulation 104 2001 257 262
5. S. Stender, and E. Hjelms In vivo transfer of cholesteryl ester from high and low density plasma lipoproteins into human aortic tissue Atherosclerosis 8 1988 252 262
6. H. Chai, S. Yan, P. Lin, A.B. Lumsden, Q. Yao, and C. Chen Curcumin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine coronary arteries J. Am. Coll. Surg. 200 2005 820 830
7. H. Chai, W. Zhou, P. Lin, A. Lumsden, Q. Yao, and C. Chen Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries Am. J. Physiol. Heart Circ. Physiol. 288 2005 H2965 H2971
8. B.S. Conklin, W. Fu, P.H. Lin, A.B. Lumsden, Q. Yao, and C. Chen HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries Cardiovasc. Res. 63 2004 168 175
9. W. Fu, H. Chai, Q. Yao, and C. Chen Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression J. Acquir. Immune Defic. Syndr. 39 2005 152 158
10. M.E. Staff, Physicians' Desk Reference 2004. 57 ed.: Medical Economics (2004).
11. L.B. Nielsen, B.G. Nordestgaard, S. Stender, and K. Kjeldsen Aortic permeability to LDL as a predictor of aortic cholesterol accumulation in cholesterol fed rabbit Arterioscler. Thromb. 12 1992 1402 1409
12. C.H. Kao, J.K. Chen, J.S. Kuo, and V.C. Yang Visualization of the transport pathways of low density lipoproteins across the endothelial cells in the branched regions of rat arteries Atherosclerosis 116 1995 27 41
13. B.R. Stevenson, and B.H. Keon The tight junction: morphology to molecules Annu. Rev. Cell Dev. Biol. 14 1998 89 109
14. H. Ozaki, K. Ishii, H. Horiuchi, H. Arai, T. Kawamoto, Okawa, A. Iwamatsu, and T. Kita Cutting edge: combined treatment of TNF-α and IFN-γ causes redistribution of junctional adhesion molecule in human endothelial cells J. Immunol. 163 1999 553 557
15. W. Wang, W.L. Dentler, and R.T. Borchard VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly Am. J. Physiol. 280 2001 H434 H440
16. K.K. Griendling, C.A. Minieri, J.D. Ollerenshaw, and J.D. Alexander Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells Circ. Res. 74 1994 1141 1148
17. UNAIDS/WHO, Report on the global AIDS epidemic, www.unaids.org. 2004.
18. Cardiovascular and metabolic complications of HIV infection, Cardiol. Rev. 8 (2000) 260-268.
19. G. Krishnaswamy, D.S. Chi, J.L. Kelley, F. Sarubbi, J.K. Smith, and A. Peiris The cardiovascular and metabolic complications of HIV infection Cardiol. Rev. 8 2000 260 268
20. D.S. Zhong, X.H. Lu, B.S. Conklin, P.H. Lin, A.B. Lumsden, Q. Yao, and C. Chen HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells Arterioscler. Thromb. Vasc. Biol. 22 2002 1560 1566
21. M.B. Lucia, S. Rutella, G. Leone, S. Vella, and R. Cauda HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART JAIDS 27 2001 321 330
22. P. Domingo, X. Matias-Guiu, R.M. Pujol, E. Francia, E. Lagarda, M.A. Sambeat, and G. Vazquez Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy AIDS 13 1999 2261 2267
23. H. Lum, and A.B. Malik Mechanisms of increased endothelial permeability Can J. Physiol. Pharmacol. 74 1996 787 800
24. M.S. Blum, E. Toninelli, J.M. Anderson, M.S. Balda, J. Zhou, L. O'Donnell, R. Pardi, and J.R. Bender Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines Am. J. Physiol. Heart Circ. Physiol. 273 1997 H286 H294
25. R. Zhao, X. Chen, Q. Yao, and C. Chen TNF-α stimulates interleukin-8 and endothelin-1 expression in human endothelial cells Biochem. Biophys. Res. Commun. 327 2005 985 992
26. R. Krams, J.J. Wentzel, J.A. Oomen, R. Vinke, J.C. Schuurbiers, P.J. de Feyter, P.W. Serruys, and C.J. Slager Evaluation of endothelial shear stress and 3D geometry as factors determining the development of atherosclerosis and remodeling in human coronary arteries in vivo Arteriscler. Thromb. Vasc. Biol. 17 1997 2061 2065
27. M. Okano, and Y. Yoshida Junction complexes of endothelial cells in atherosclerosis-prone and atherosclerosis-resistant regions on flow dividers of brachiocephalic bifurcations in the rabbit aorta Biorheology 31 1994 155 161
28. M. Aslan, T.M. Ryan, T.M. Townes, L. Coward, M.C. Kirk, S. Barbes, C.B. Alexander, S.S. Rosenfeld, and B.A. Freeman Nitric oxide-dependent generation of reactive species in sickle cell disease: actin tyrosine nitration induces defective cytoskeletal polymerization J. Biol. Chem. 278 2003 4194 4204
29. G.M. Rubanyi, and P.M. Vanhoutte Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor Am. J. Physiol. 250 1986 H822 H827
30. A.L. Baldwin, G. Thurston, and H. al Naemi Inhibition of nitric synthesis increases venular permeability and alters endothelial actin cytoskeleton Am. J. Physiol. 274 1998 H1776 H1784
31. S.R. Husain, J. Cillard, and P. Cillard Hydroxyl radical scavenging activity of flavonoids Phytochemistry 26 1987 2489 2491
32. K. Nagai, M.H. Jiang, J. Hada, T. Nagata, Y. Yajima, S. Yamamoto, and T. Nishizaki (-)-Epigallocatechin gallate protects against NO stress-induced neuronal damage after ischemia by acting as an anti-oxidant Brain Res. 956 2002 319 322
33. C.B. Allan, G.M. Lacourciere, and T.C. Stadtman Responsiveness of selenoproteins to dietary selenium Annu. Rev. Nutr. 19 1999 1 16
34. H. Cai, and D.G. Harrison Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress Circ. Res. 87 2000 840 844